Literature DB >> 11695198

Net survival: comparison between relative and cause-specific survival estimates.

E Crocetti1, V De Lisi, L Gafà, O Sechi, L Mangone.   

Abstract

This paper presents a comparison between cause-specific survival and relative survival calculated according to the Hakulinen method. The data are from the Tuscany Cancer Registry and we analysed the following cancer sites: stomach, colon, rectum, cervix and corpus uteri, female breast and skin melanoma. When cause-specific survival was calculated including among the deceased only those subjects whose death certificate reported strictly the same neoplasm as cause of death (three digits ICD-9), very good agreement between the two methods was found for stomach, lung, and skin melanoma and a good agreement was found for female breast. For cancer of the colon and rectum, in order to obtain similar estimates, deaths coded as caused by cancer in other sites of the large bowel and partially the not specified intestine had to be included. For cancer of the cervix and corpus uteri, in order to obtain similar estimates, but with cause-specific remaining higher than the relative estimates, deaths coded as not specified uteri cancer had to be included. In conclusion, cause-specific survival may be used also with overall mortality data, providing the death causes by cancers most susceptible to misclassification are to be included. However, using cause-specific survival creates some difficulties in comparative studies due to the different reliability of mortality data and to the different criteria used to identify the main cause of death.

Entities:  

Mesh:

Year:  2001        PMID: 11695198

Source DB:  PubMed          Journal:  Epidemiol Prev        ISSN: 1120-9763            Impact factor:   1.901


  1 in total

1.  On the use of flexible excess hazard regression models for describing long-term breast cancer survival: a case-study using population-based cancer registry data.

Authors:  R Schaffar; A Belot; B Rachet; L Woods
Journal:  BMC Cancer       Date:  2019-01-28       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.